BMS names Fouad Namouni as new oncology development head
pharmafile | July 26, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo
Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. In his new position, Namouni will be responsible for leading the execution of a comprehensive development strategy for the company’s oncology pipeline from the early development stage through commercialisation. He will continue to report to executive vice president and chief scientific officer Francis Cuss, and will remain a member of the R&D leadership team.
“Fouad has demonstrated highly successful strategic and visionary leadership in oncology and immuno-oncology drug development and medical affairs throughout his career at Bristol-Myers Squibb,” said Cuss. “As a trained paediatric oncologist, Fouad brings to this role exceptional clinical experience and an unwavering commitment to patients. I am confident that our oncology development programs will continue to thrive under his leadership.”
Namouni joined BMS in France in 1999 as life-cycle manager for chemotherapy drug Taxol and has held positions of increasing responsibility in R&D since. Namouni moved to the U.S. in September 2006 where he became responsible for the development of metastatic colorectal cancer treatment Erbitux. He most recently served as head of medical, leading the worldwide medical organization and prior to that, was the development lead for Yervoy and Opdivo.
In addition, the company has announced today that Michael Giordano has retired from BMS after more than 17 years of leadership and service. Since joining the company, Giordano and the teams he has led have developed and delivered more than a dozen medicines to patients, marking a successful and distinguished drug development career.
Related Content
Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
NICE approves first treatment for obstructive HCM for NHS use
The National Institute for Health and Care Excellence (NICE) has announced that it has approved …
